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MENTAL HEALTH - Clinical Outcomes Studies
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OBJECTIVES: Drug-Related Problems (DRPs) occur frequently with antidepressants
leading to treatment failure and increasedmorbidity in the depressed patient. The
study was designed to collect preliminary data related to antidepressant drug re-
lated problems and treatment failure in India.METHODS: A cross sectional obser-
vational study was carried out for a period of four months at a mental health
facility in Udupi, India. All the prescriptions of the study population were screened
for Drug Related Problems (DRPs) such as ADRs and DDIs by using a computerized
database system. These data were assessed for the pattern of the ADRs with re-
spect to patient demographics, nature of the reaction, outcome of the reactions,
causality, severity and preventability. RESULTS: A total of 120 patients were en-
rolled in the study and 33 of them developed 50 Drug Related Problems (DRPs), in
those 24 Drug-Drug Interactions (DDIs) and 26 Adverse Drug Reactions (ADRs). The
overall incidence of DRPs in the present study was 27.5%. Among the 33 patients
and the significant proportions of DRPs were in female with [p 0.01] than inmale.
Most of the patients who had developed DRPs was in the age group of 36-55 yrs
[p0.01] followed by other age. The common ADRs observed were hyponatremia
and headache. Considering outcomes, 20 (76.9%) of cases recovered fromADRs and
while assessing the preventability, 20 (76.9%) of the ADRs were definitely prevent-
able. When causality assessments were conducted, we found that that majority of
ADRs were probable and were found to be mild to moderately severe.
CONCLUSIONS:An ongoing drugmonitoring program aimed at assessing common
drug-related problemsmay be key in improving treatment effectiveness in patients
with depression. The involvement of community pharmacists in a pilot psychiatric
drugmonitoring program in India assisted in the identification of common adverse
drug related problems in these patients.
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A large number of depressed patients remained unremitting despite existing
classes of antidepressants (SSRI,SNRI andNaSSa). ShouldAgomelatine, a new class
of antidepressant reflect different clinical value in daily practice? OBJECTIVES: To
evaluate clinical value and safety of Agomelatine on basis of daily practice inman-
agement of depressive disorders.METHODS: Newly diagnosed depressed and un-
remitting depressed patients diagnosed by psychiatrists (per DSM-IV criteria) were
prescribed Agomelatine 25 mg daily, followed-up at week 2, 6, 12 respectively. At
follow-up, efficacy of Agomelatine were assessed with the 10-items standardized
Thai version MA¨DRS, Clinical Global Improvement score (both CGI-S, CGI-I) by
psychiatrists. Acceptability and safety were assessed through direct patients’
interviews. RESULTS: 133 depressed patients, mean duration of illness of 4.3 years,
mean number of episodes of 2.4. Anxiety disorder and Insomnia were diagnosed in
12.8% and 8.3% of patients respectively. 63% and 37% of patients were treated with
Agomelatine as monotherapy and combination with other psychotropic agents.
The efficacy assessment as reflected by mean MA¨DRS score reduction based on
MA¨DRS severity level. The mean(SD) MA¨DRS score for all patients (N133), pa-
tients with MA¨DRS  20(N67), MA¨DRS between 20-24(N32) and MA¨DRS 
25(N34) at baseline of 21.40(5.25),16.91(1.75), 23.6(1.38) and 28.7(1.93) were signif-
icantly reduced with mean score reduction (95% CI)at p0.001 by 10.2(9.3-11.1),
6.3(5.8-6.8), 11.2(10.0-12.5) and  16.9(15.5-18.2) at the end of 12-weeks respec-
tively. The clinical global improvement of depression after 12 week measured by
mean (SD) of CGI-S and CGI-I significantly improved for all patients at 1.65(0.79)
and 3.7(1.02) respectively with therapeutic index of 2.52 (1.11). The reported
adverse effects were mild and transient, mainly dizziness and headache. No sus-
pect case of abnormal liver enzyme was noted. CONCLUSIONS: Agomelatine is a
clinically effective, well-tolerated antidepressant in Thai depressed patients what-
ever the severity of depression. Agomelatine is endowed with moderate to high
therapeutic value for management of depressive disorders in Thailand.
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OBJECTIVES: Dementia is a progressive disease characterized by behavioral, func-
tional, and cognitive deficits that affects patients and their families on multiple
levels. The aim of this study was to estimate the impact of dementia care on
caregivers at personal, emotional, social, professional, and financial levels in
China.METHODS:Amulticenter, cross-sectional hospital based study in dementia
patients was conducted between September 2009 and December 2009 in 48 Tier 3
hospitals across seven regions ofmainland China. Patients with suspected demen-
tia and their caregivers were given the option to participate and complete an In-
formedConsent Form. Consented patients underwent standard dementia and sub-
type diagnosis using criteria from Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV). Level of caregiver burden was measured using the Chinese
validated Zarit Burden Interview (ZBI), which was designed to reflect the stresses
experienced by caregivers of dementia patients. Costs were converted into US
dollars (6.83 Yuan 1 USD). RESULTS: A total of 1425 caregivers participated in the
caregiver assessment interview. Results showed that dementia care had the great-
est impact on the professional lives of caregivers, with 25.3% of all respondents
reporting a reduction to their work schedule in the past month and a greater re-
duction in work hours compared with counterparts who cared for patients with
newly diagnosed dementia. With regard to personal, social, and emotional well-
being, most caregivers reported that dementia care had little to no impact. Costs
associated with dementia care ranged $55–$214 (USD) and total cost averaged $575
(USD) per month. This amount exceeds the reported per capita disposable income
of urban dwellers ($210). CONCLUSIONS: The results reported here are the first to
describe the burden of dementia care among a cohort of caregivers in China, and
provides some insight into the obstacles facing the country with the fastest grow-
ing elderly population in the world.
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OBJECTIVES: In Taiwan, the ratio of aging population is gradually increasing and
nowadays the old age depression becomes amajor issue of themental disorder and
integration disease prevention program. Also, the old age people always suffered
from multiple chronic diseases; thus, the association of the diseases and medica-
tions could be studied in order to develop the geriatric pharmaceutical care model.
METHODS: The claims database of 2000 to 2011 from the Kaohsiung Veterans
General Hospital was used to select all the cases from the old age people (65yrs.).
By using the anatomical therapeutic and chemical classification system, we sort
out all the depression cases of the ATC code N06A for further evaluation. All the
statistical work was completed using SPSS 19.0 Base for windows. RESULTS: There
were 92,975 cases matched the acceptance criteria and a total of 10,310 patients
identified inwhich 6836weremale and 3474were female. Themedian age formale
was 79 years old whereas 76 years old for female. During the 12-year study period,
the median length of drug day for male was 56 days ranged from 2 to 5,276 longer
than 44 ranged from 3 to 4,868 days for female. There was statistical significance
difference (p0.01) for gender usingMann-Whitney Test. CONCLUSIONS:Owing to
the change from off pattern drugs to generic drugs like the selective serotonin re-
uptake inhibitor, Prozac, the drug fee has made a remarkable decrease during these
years. Instead, the tetra-cyclic antidepressant i.e. mirtazapine and the serotonin-nor-
epinephrine reuptake inhibitors i.e. milnacipran have increased significantly.
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OBJECTIVES: This study examined whether participation in a weight control pro-
gramwas also associated with improvements in clinical and functional outcomes.
METHODS: A post hoc analysis was conducted using data from the Chinese sub-
group (n330) of amulticountry, 6-month, prospective, observational study of out-
patients with schizophrenia who were initiated or switched to oral olanzapine. At
study entry, and each month for 6 months, participants were assessed with the
Clinical Global Impression of Severity (CGI-S), and measures of patient insight and
functional status. Change in level of illness severity, response rate, and time to
response (all per CGI-S), impaired work activities and insight level were compared
between two groups: 1) 153 patients who participated in a weight control program
at study entry or during the study (WCP), and; 2) 177 patients who did not partici-
pate in theweight control programat any timeduring the study (NWCP). Univariate
comparisons were conducted using Fisher’s exact tests for categorical variables
and ANOVA for continuous variables. Kaplan-Meier survival analysis was used to
assess time to response. RESULTS: Participants had amean age 29.0 years and 29.3
years, and 51.0% and 57.6% were female for WCP and NWCP, respectively. Average
initiated daily dose for olanzapine was 9.5  5.4mg. Weight control program par-
ticipants gained less weight than non-participants (LSmeans weight change: 3.9kg
vs. 4.9kg, p0.03) and showed statistically significant better clinical and functional
outcomes: greater improvement in illness severity (2.93 vs2.06 p0.001), higher
treatment response rates (94.1% vs 80.9% p0.001), shorter time to response
(p0.001), higher proportion of patients without impaired work activities
(p0.001), and greater improvement in patients’ insight (p0.001). CONCLUSIONS:
Participation in a weight control program may not only lower the risk of clinically
significant weight gain in olanzapine-treated patients, but may also be associated
with additional clinical and functional benefits.
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OBJECTIVES:With rapid ageing, prevalence of dementia in the elderly is increasing
at a fast rate. This study aimed to examine themedical expenditure for dementia in
the elderly and to analyze factors affecting its expenditure in South Korea.
METHODS:We analyzed the data of sampled patients from National Health Insur-
ance. Direct medical costs including hospitalization, out-patient service and phar-
macy costs were calculated from claims of patients in 2010. To examine the deter-
minants of costs, we used a two-part model to deal with the zero values of
expenditure. The first part predicted the probability of any expenditure with a
logistic regression while the second part used an OLS regression model with log-
transformed expenditure. RESULTS: Average medical expenditure in the total of
3729 dementia patients was 5.6 million won. Average expenditure increased with
severity (p0.004). In the first part, patients in the long-term care facilities had a
lower probability of expensing medical costs than patients with family-based care
(OR0.30, 95% CI 0.21-0.43). The probability of incurring expenditure was much
higher for severe patients thanmild patients (OR1.33, 95% CI 1.02-1.74). Among
the patients with expenditure, better educated (elementary, middle school gradu-
ates and high school graduates) spent more costs than under educated (less than
elementary graduates) patients (17%, 27%, respectively) (p0.05). Cost estimates
demonstrated that education levels, facility care and types of dementia were sig-
nificantly associated with the costs. Interestingly, the costs were 20% lower for
severe patients versus mild patients because outpatient and pharmacy costs de-
creased as the severity increases. CONCLUSIONS: This study showed a burden of
medical expenditure for dementia and associations between various factors and
costs. Costs were significantly different among conditions. However, this study
considered only medical costs for dementia. Therefore, further research needs to
include non-medical costs and indirect costs for dementia.
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OBJECTIVES: To review the consequences associated with schizophrenia relapse.
METHODS:We searched the Medline, EBSCO and EMBASE up to February 2012 for
eligible studies. Included studies were systematic reviews, meta-analyses, pro-
spective observational studies, retrospective cohort studies or randomized con-
trolled trials (RCTs) measuring the cost consequences of schizophrenia relapse or
recurrence. The consequences from studies with different designs, countries and
years were compared. RESULTS: Eleven studies conducted in Europe, United
States, Germany, England, Australia, Japan and Brazil were identified and re-
viewed. Relapse in schizophrenia were characterized by higher rates of hospital-
ization, day hospital visit and psychiatric visit; longer inpatient days and more
medications. Schizophrenia patients with relapse incurred significantly higher to-
tal annual direct medical costs, which were almost 2 to 4 times of those without
relapse. The absolute annual cost of relapsed schizophrenia patients changed tre-
mendously in different countries, approximately ranging from 1,198 USD (in 2006
USD) in Brazil to 50,986 USD (in 2000 USD) in the United States. The average cost of
a relapse was 3421 EUR (in 2005 EUR). The driving part of the cost difference was
attributed to inpatient care. Higher frequencies of reemergence of psychotic symp-
toms and aggravation of positive or negative symptoms were observed in these
studies. Significant differences in patient quality of life in favor of patients without
relapsewere captured in some of the studies, while in other studies the differences
were insignificant. The most frequently employed quality of life measurements
were PANSS, CGI, GAF, Lehman QoL, EQ-5D, MLDL GI and SF-36. CONCLUSIONS:
The findings of the review confirmed the significant economic burden of schizo-
phrenia relapse, and showed such costs were mainly driven by more hospitaliza-
tions and longer duration of hospitalization. The cost consequence of relapse var-
ies among countries. Relapse causes deterioration in patient quality of life as well.
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OBJECTIVES:To analyze the cost consequences associatedwith non-compliance in
schizophrenia treatment.METHODS:We searched the Pubmed, EBSCO, Adis Phar-
macoEconomics, Wiley, Springer and Elsevier up to February 2012 for eligible stud-
ies using the key words of schizophrenia, compliance, adherence and cost. In-
cluded studies were systematic reviews, meta-analyses, prospective observational
studies and retrospective cohort studies measuring the cost consequences related
to non-compliance of anti-psychotic medication. The cost consequences from dif-
ferent studies were compared. RESULTS: Six primary studies and seven literature
reviews were identified and included in this analysis, of the primary studies 2 in
UK, 1 in Sweden, 1 in Canada and 1 in Taiwan. Non-compliance with treatment is
the main driver of relapses and re-hospitalizations which cause significant eco-
nomic burden to patients and their families. Schizophrenia patients who were not
compliant with treatment hadmore relapses, higher rates of hospitalizations, lon-
ger hospitalization days,more needs for intensive care,more psychiatric visits, and
more medications. One of the UK studies showed that non-compliant patients
incurred significantly higher total annual direct medical costs, which were almost
1.5 times of those who were compliant with treatment. The other 5-year UK study
showed that if we improve compliance rate for a patient by 20%, £16,147 will be
saved and 0.55 relapse will be avoided for the patient. Three studies showed a
significant increase of compliance by using long-acting Risperidone injection com-
pared with oral anti-psychotics and long-acting typical anti-psychotic injections
which may result in cost savings and improvement in patient quality of life.
CONCLUSIONS: The findings of the review showed significant cost saving by in-
creasing compliance with treatment due to reductions in relapse and re-hospital-
ization. Long-acting Risperidone injection can significant increase the compliance
of medication which may result in cost savings.
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OBJECTIVES: To compare cost-effectiveness of Agomelatine versus Escitalopram-
Venlafaxine matrix comparator in terms of Life Year in Remission (LYR) and Qual-
ity Adjusted Life Year (QALY).METHODS: A discrete event simulation hypothetical
model was developed to describe the course of depressive disorders treatment in
Thai setting. A sample size of 250,000 depressed patients and 1,000 simulations
were generated. Antidepressants were analysed for treatment of acute phase
(12-24 weeks), continuation phase (6-9 months) and maintenance phase (over 2
years of follow-up). Model was based on real Thai data, which acquired from public
data, including disease parameters, costs of antidepressants, costs of medication
treatments for insomnia and sexual side-effects, costs of cognitive behavioral
therapy(CBT) and electroconvulsive therapy(ECT), mean costs of psychiatric visits
and mortality data. Impact measures were derived from a systematic review and
meta-analysis of international literature. Willingness to pay was set at 300,000
THB/QALY. Results were presented as costs (Thai Baht currency) per QALY and per
LYR averted, compared to thematrix comparator which contained 41.8% venlafax-
ine-treated and 58.2% escitalopram-treated in real Thai data. Model simulation
initiated with either Agomelatine 25 mg or a Matrix comparator (80% with Escita-
lopram 10mg, 20% with Escitalopram 20mg 20% or Venlafaxine150 mg). Relapse
cases need treatment assumed addition of Sertraline, CBT and ECT. RESULTS: The
IncrementalCost-EffectivenessRatios (ICER)ofAgomelatine forepisodic treatmenteither
with or without a continuation of maintenance phase at base case was more effective
than thematrix comparator by177,008THB per LYR and100,767THB per QALY. Prob-
abilistic sensitivity analysis supported thatAgomelatinewasmore cost effective than the
matrix comparator at probability above 0.75. CONCLUSIONS: In Thai setting, Agomala-
tinewasamorecost-effective treatmentoption fordepressivedisordersascompared toa
matrix comparator of EscitalopramandVenlafaxine.
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OBJECTIVES: To evaluate the cost-effectiveness of Risperidone long-acting injec-
tion (LAI) in schizophrenia treatment. METHODS: We searched medical literature
using key words risperidone, long-acting, cost-effectiveness, pharmacoeconomics
and economic evaluation in Medline, Embase, Elsevier and Ovid databases up to
January 2012. Literature review studies were excluded from this review. RESULTS:
Twelve primary study articles were indentified and included in this review of
which 2 in Germany, 2 in Sweden, 1 in US, 1 in France, 1 in Belgium, 1 in the UK, 1
in New Zealand, 1 in Canada, 1 in China Mainland, 1 in Taiwan. All studies only
calculated the direct costs of treatments, including hospitalizations, medications,
and consultations. Ten studies showed cost savings while the rest 2 studies con-
cluded Risperidone LAI was more cost-effective than comparators. Among the 10
studies showing cost savings, 4 studies further demonstrated better efficacy of
Risperidone LAI than oral psychotics and Haloperidol long-acting injection, 4 stud-
ies showed a range of 0.22-0.55 relapses reduction with Risperidone LAI treatment
resulting in significant cost savings, 2 studies showed a 0.043-0.103 QALY gained
per patient in 5 years with Risperidone LAI, 3 studies compared the inpatient days
and hospitalization frequencies before and after using Risperidone LAI with fewer
inpatient days and hospitalizations after Risperidone LAI treatment. Among the 2
studies showing Risperidone LAI wasmore cost-effective, the study in ChinaMain-
land showed Risperidone LAI was more cost-effective than Olanzopine and Que-
tiepine while the study from Taiwan found Risperidone LAI was more cost-effec-
tive than Olanzopine and depot haloperidol. CONCLUSIONS: Based on the
available studies, this systematic review found that Risperidone LAI was a cost-
effective treatment for schizophrenia patients.
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MEDICATION ADHERENCE, DIABETIC CARE AND RISK OF ACUTE
COMPLICATIONS OF TYPE II DIABETICS WITH SCHIZOPHRENIA RECEIVING
ORAL HYPOGLYCEMIC THERAPY
Cheng JS1, Shih YT2
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Jhu-Nan, Mioli, Taiwan
OBJECTIVES: Schizophrenia has been found to be associated with poor medication
adherence, and a higher prevalence of diabetes. As appropriate adherence to hy-
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